OncoMatch/Clinical Trials/NCT03697356

R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

Is NCT03697356 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lenalidomide, Bortezomib, Rituximab, Dexamethasone for waldenström's macroglobulinemia.

Phase 2RecruitingKosin University Gospel HospitalNCT03697356Data as of Jun 2026Location: South Korea

Treatment: Lenalidomide, Bortezomib, Rituximab, Dexamethasone — A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia (Ballondor trial)

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Lenalidomide, Bortezomib, Rituximab, Dexamethasone

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 19

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: (rituximab, lenalidomide, bortezomib)

Patients who have received rituximab, lenalidomide, or bortezomib

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥1,000 / μL; Platelet count ≥75,000 cells / μL when not transfused

Kidney function

Renal failure requiring hemodialysis or peritoneal dialysis [excluded]

Liver function

Serum AST / ALT ≤ 3 times the upper limit of normal

Cardiac function

Patients with uncontrolled severe heart disease [excluded]; Patients with acute diffuse invasive pulmonary disease and cardiovascular disease [excluded]

Appropriate bone marrow, liver, and kidney function; Absolute neutrophil count (ANC) <1,000 / μL [excluded]; Platelet count <75,000 cells / μL when not transfused [excluded]; Serum AST / ALT> 3 times the upper limit of normal [excluded]; Renal failure requiring hemodialysis or peritoneal dialysis [excluded]; Patients with uncontrolled severe heart disease [excluded]; Patients with acute diffuse invasive pulmonary disease and cardiovascular disease [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03697356 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify